What are the clinical features, laboratory findings, diagnostic criteria, and management of Dubin‑Johnson syndrome?

Dubin-Johnson Syndrome: Clinical Features, Diagnosis, and Management

Overview

Dubin-Johnson syndrome (DJS) is a benign autosomal recessive disorder caused by mutations in the ABCC2 gene (encoding MRP2 transporter), resulting in chronic conjugated hyperbilirubinemia with an excellent long-term prognosis requiring only conservative management. 1, 2, 3

Clinical Features

Presentation Patterns

• Recurrent jaundice is the hallmark clinical manifestation, often beginning in infancy or childhood, though diagnosis may be delayed until adolescence or adulthood 1, 2
• Asymptomatic conjugated hyperbilirubinemia discovered incidentally is common, as most patients lack symptoms 2
• Abdominal pain may accompany jaundice episodes, though this is not universal 2
• Jaundice from birth with a positive family history should raise suspicion for DJS 2

Key Clinical Characteristics

• Patients typically have normal life expectancy and require no specific treatment beyond conservative management 2
• The condition is characterized by chronic or intermittent conjugated hyperbilirubinemia without other significant liver dysfunction 1, 4
• No stigmata of chronic liver disease are present on physical examination 5

Laboratory Findings

Distinctive Biochemical Pattern

DJS presents with a characteristic enzyme pattern that distinguishes it from other causes of neonatal cholestasis, particularly biliary atresia: 1

• Conjugated (direct) hyperbilirubinemia is the defining laboratory abnormality 1, 2
• Near-normal or minimally elevated AST and ALT (significantly lower than in biliary atresia, P < 0.001 and P = 0.002 respectively) 1
• Low or normal gamma-glutamyl transferase (GGT) (significantly lower than biliary atresia, P < 0.001) 1
• Normal alkaline phosphatase in most cases 1

Overlapping Features with Other Conditions

• Total serum bilirubin, serum bile acids, and stool color may not reliably discriminate DJS from biliary atresia in neonatal presentations 1
• Other hepatic biochemistry parameters remain normal 4

Diagnostic Criteria and Testing

First-Line Diagnostic Tests

Urine coproporphyrin analysis (UCA) is the fastest and most reliable non-invasive diagnostic tool for DJS: 1

• UCA shows altered coproporphyrin isomer ratio with predominance of coproporphyrin I (normally coproporphyrin III predominates) 1, 4
• This test should be performed in every infant with neonatal cholestasis and atypical liver enzyme pattern to avoid unnecessary invasive procedures 1

Confirmatory Testing

Genetic analysis for ABCC2 mutations is recommended for definitive diagnosis: 1, 3

• Sequencing identifies disease-associated ABCC2 variants confirming the diagnosis 1
• Mutations are concentrated in the ATP-binding-cassette domains (particularly the first ATP-binding cassette) and adjacent transmembrane domains 3
• All identified mutations to date affect the cytoplasmic domain of the MRP2 transporter 3

Liver Biopsy Findings

When performed, liver biopsy reveals pathognomonic features: 1, 4, 5

• Black or dark brown liver due to melanin-like pigment deposition in hepatocytes 4, 5
• Preserved hepatic architecture without cirrhosis or significant fibrosis 5
• Intracellular accumulation of dark melanin-like pigment is characteristic 4

Additional Diagnostic Modalities

• Laparoscopy-facilitated liver biopsy provides direct visualization and safe tissue sampling 4
• Oral cholecystography may show non-visualization or delayed visualization of the gallbladder 4
• Bromsulphalein (BSP) test shows characteristic biphasic retention pattern but is no longer recommended due to potential severe adverse effects 4
• 99mTc-HIDA cholescintigraphy may be used but is not essential for diagnosis 4

Differential Diagnosis Considerations

Critical Distinction from Biliary Atresia

In neonatal cholestasis presentations, DJS must be distinguished from biliary atresia to prevent unnecessary surgery: 1

• The combination of low AST, ALT, and GGT with conjugated hyperbilirubinemia strongly suggests DJS over biliary atresia 1
• Urine coproporphyrin analysis should be performed before considering invasive procedures like intraoperative cholangiography 1

Other Differential Diagnoses

• Other hereditary hyperbilirubinemias (Rotor syndrome, Crigler-Najjar syndrome) differ in conjugated vs. unconjugated bilirubin patterns and clinical presentation 2
• Acquired causes of conjugated hyperbilirubinemia should be excluded through appropriate testing 1

Management

Conservative Approach

No specific treatment is required for DJS; management is entirely supportive: 2

• Reassurance that the condition is benign with normal life expectancy 2
• Avoidance of unnecessary invasive testing once diagnosis is confirmed 1
• No dietary restrictions or medications are needed 2

Monitoring and Follow-Up

• Periodic clinical follow-up to monitor for jaundice episodes and provide reassurance 2
• No specific laboratory monitoring is required once diagnosis is established 2
• Patients should be counseled about the benign nature and excellent prognosis of the condition 1, 2

Genetic Counseling

• Autosomal recessive inheritance pattern should be explained to families 1, 3
• Genetic counseling is appropriate for family planning, particularly when both parents are known carriers 3

Clinical Pitfalls to Avoid

• Do not subject patients to unnecessary invasive procedures (e.g., liver biopsy, ERCP) when non-invasive testing (UCA and genetic analysis) can establish the diagnosis 1
• Do not misdiagnose as biliary atresia in neonatal presentations; the characteristic low transaminase and GGT pattern should prompt consideration of DJS 1
• Do not perform BSP testing due to risk of severe adverse reactions when safer alternatives exist 4
• Do not overlook DJS in patients with recurrent jaundice and normal liver architecture on imaging 2